Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

摘要: PURPOSEAlthough most patients with indolent lymphomas respond to initial therapy, virtually all experience relapse. Secondary therapy is often beneficial, but responses are rarely, if ever, durable. We conducted this phase II trail evaluate the therapeutic efficacy and toxicity of fludarabine, mitoxantrone, dexamethasone (FND) in relapsed lymphoma.PATIENTS AND METHODSFifty-one recurrent or refractory lymphoma were treated a regimen fludarabine 25 mg/m2/d intravenously (IV) on days 1 3, mitoxantrone 10 mg/m2 IV day 1, 20 mg/d orally 5. Treatment was repeated at 4-week intervals for maximum eight courses. Late course trial, trimethoprim-sulfamethoxazole (TMP-SMX) incorporated Pneumocystis carinii (PCP) prophylaxis.RESULTSResponses complete (CR) 24 (47%) partial (PR) (47%). The median failure-free survival time 21 months CR 9 month...